-
STAT+: With questions surrounding its gastric cancer drug, Amgen fills in some gaps
20 Oct 2025 20:48 GMT
… drewqjoseph.45.
BERLIN — In June, Amgen reported that an experimental drug …
-
Amgen, AZ's Tezspire challenges Dupixent in nasal polyps
20 Oct 2025 12:55 GMT
Amgen and AstraZeneca's Tezspire … sales territory with AZ and Amgen reporting combined turnover of more … relief," said Jay Bradner, Amgen's R&D … be on the way for Amgen and AZ after the drug …
-
Amgen joins forces with Welsh partners to accelerate healthcare innovation and improve patient outcomes
20 Oct 2025 11:05 GMT
… Vice President and General Manager, Amgen UK & Ireland said:
… made from this agreement with Amgen, Swansea University, Life … with a shared purpose. Amgen’s commitment to value- … benefits society. This partnership with Amgen, the Welsh Government, and …
-
#ESMO25: Amgen, Zai Lab detail reduced survival benefit in stomach cancer trial
19 Oct 2025 23:12 GMT
-
AstraZeneca-Amgen Tezspire gets USFDA nod for chronic rhinosinusitis with nasal polyps
18 Oct 2025 11:24 GMT
The approval by the US Food and Drug Administration (FDA) was based on efficacy and safety data from the WAYPOINT Phase III trial, which were presented at the 2025 American Academy of Allergy Asthma & Immunology (AAAAI)/World Allergy Organization ( …
-
Amgen and AstraZeneca says US FDA broadens indication for Tezspire
18 Oct 2025 05:01 GMT
(Alliance News) - Amgen Inc and AstraZeneca on … , Thousand Oaks, California-based Amgen and Cambridge, England-based AstraZeneca … severe asthma.
In 2020, Amgen and AstraZeneca updated the 2012 … mid-single-digit royalty to Amgen.
Amgen closed up 0.4% at …
-
Amgen, AZ's Tezspire gains 2nd FDA nod, upping the ante in its battle with Dupixent
18 Oct 2025 04:21 GMT
… U.S. regulator has endorsed Amgen and AstraZeneca’s Tezspire as … Tansey Chevlen, who heads up Amgen’s commercial efforts for its …
-
Amgen, AstraZeneca gets FDA nod for Tezspire
18 Oct 2025 03:54 GMT
… /iStock via Getty Images Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN …
-
US FDA expands use of Amgen, AstraZeneca's drug for chronic inflammatory sinus disease
17 Oct 2025 23:09 GMT
… and Drug Administration has approved Amgen and AstraZeneca’s drug for … head of inflammation portfolio at Amgen.
Other approved treatments for chronic …
-
US FDA expands use of Amgen, AstraZeneca’s drug for chronic inflammatory sinus disease
17 Oct 2025 21:28 GMT
… and Drug Administration has approved Amgen and AstraZeneca’s drug for … head of inflammation portfolio at Amgen.
Other approved treatments for chronic …
About
© 1995-2025